Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Integrated whole genome and transcriptome sequencing can unveil distinct molecular subgroups in pancreatic cancer (PDAC). The COMPASS trial (NCT02750657) enrolled 268 patients with advanced PDAC; ...
Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC). Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results